These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 35532298)
21. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818 [TBL] [Abstract][Full Text] [Related]
22. Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions. Chojnacka M; Diamond B; Landgren O; Maura F Semin Oncol; 2022 Feb; 49(1):11-18. PubMed ID: 35168813 [TBL] [Abstract][Full Text] [Related]
23. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Willrich MAV; Murray DL; Kyle RA Clin Biochem; 2018 Jan; 51():38-47. PubMed ID: 28479151 [TBL] [Abstract][Full Text] [Related]
25. Multiple myeloma: clinical features and indications for therapy. Dispenzieri A; Kyle RA Best Pract Res Clin Haematol; 2005; 18(4):553-68. PubMed ID: 16026737 [TBL] [Abstract][Full Text] [Related]
26. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM; Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118 [TBL] [Abstract][Full Text] [Related]
27. Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models. Hill E; Dew A; Morrison C; Yuan C; Stetler-Stevenson M; Landgren O; Kazandjian D JAMA Oncol; 2021 Jan; 7(1):132-134. PubMed ID: 33211080 [TBL] [Abstract][Full Text] [Related]
28. The Difficulty in Defining the True High-Risk Smoldering Myeloma. Weinhold N; Rasche L Clin Cancer Res; 2024 Oct; 30(19):4263-4265. PubMed ID: 39047171 [TBL] [Abstract][Full Text] [Related]
29. The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma. Yi Z; Ma T; Liu J; Tie W; Li Y; Bai J; Li L; Zhang L Front Immunol; 2022; 13():925266. PubMed ID: 35958625 [TBL] [Abstract][Full Text] [Related]
38. How I approach smoldering multiple myeloma. Vaxman I; Gertz MA Blood; 2022 Aug; 140(8):828-838. PubMed ID: 35576526 [TBL] [Abstract][Full Text] [Related]
39. The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact. Kunacheewa C; Manasanch EE Expert Rev Hematol; 2021 Dec; 14(12):1059-1069. PubMed ID: 34550841 [TBL] [Abstract][Full Text] [Related]
40. Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. Bustoros M; Kastritis E; Sklavenitis-Pistofidis R; Liu CJ; Hornburg K; Kanellias N; Kim G; Liu D; Gavriatopoulou M; Marinac CR; Roussou M; Migkou M; Noonan K; Reyes K; Rivotto B; Neuse CJ; Ziogas DC; Laubach J; Terpos E; Anderson KC; Richardson PG; Ghobrial IM; Dimopoulos MA Am J Hematol; 2019 May; 94(5):E146-E149. PubMed ID: 30773670 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]